Macrophage activation syndrome
Swedish Orphan Biovitrum AG supports clinical research in macrophage activation syndrome across systemic juvenile idiopathic arthritis and adult-onset Still’s disease, with interest in severe hyperinflammation and immune dysregulation in both children and adults.
- Systemic juvenile idiopathic arthritis
- Adult-onset Still’s disease
- Hyperinflammatory syndrome
Its research activity in this area also extends to pediatric and adult rheumatology, reflecting a focus on life-threatening inflammatory complications.
Systemic lupus erythematosus
The sponsor is also engaged in studies of macrophage activation syndrome associated with systemic lupus erythematosus, including both pediatric lupus and adult lupus populations.
- Pediatric systemic lupus erythematosus
- Adult systemic lupus erythematosus
- Secondary macrophage activation syndrome
This area highlights interest in severe autoimmune inflammation and the management of rare, rapidly progressing complications linked to lupus.
Rare inflammatory disorders
Swedish Orphan Biovitrum AG’s clinical portfolio reflects a strong focus on rare inflammatory disorders with urgent unmet needs, especially conditions marked by immune overactivation and systemic tissue injury.
- Rare immune-mediated disease
- Systemic inflammation
- Severe inflammatory complications
Within this therapeutic domain, the sponsor’s research interest centers on difficult-to-treat syndromes requiring specialized immunology expertise.
Pediatric and adult immunology
The sponsor’s research landscape spans both pediatric and adult patient groups, with attention to immune-mediated disease across different age ranges.
- Pediatric immunology
- Adult immunology
- Autoimmune inflammation
This cross-age focus is particularly relevant for syndromes where systemic immune activation presents in overlapping rheumatologic and autoimmune settings.
